Menu
17/08/2004
New plans to focus on providing better medicines for children
A new initiative to encourage the development of more medicines designed specifically for use in children has been announced today by the government.
The new paediatric medicines strategy is aimed at encouraging manufacturers of medicines to research and develop medicines geared to the needs of children. They will also make sure prescribers have better information about the impact of medicines on children.
Most medicines are designed for and tested on adults but are widely prescribed for children. The government has said the move is necessary as children and adults "respond very differently to medicines" and that a treatment which is effective in adults may not be as suitable for children.
Under the plans, part of the additional £100 million announced in the Budget to promote research into medicines for children will be invested through new research networks coordinated by the UK Clinical Research Collaboration.
Better information on the use of medicines on children in patient information leaflets and strongly encouraging companies to provide much better paediatric clinical trial data for new and current medicines also form part of the strategy.
Health Minister Lord Warner said: "I want the new strategy that I have announced today to give a strong message to pharmaceutical companies to focus on the needs of children when developing new medicines. Health professionals need the latest information so that they can make the right choices about the medicines and treatments for their younger patients, and that is why the new British National Formulary for Children is so important".
Professor Rosalind Smyth, Chair of the Committee on Safety of Medicines Paediatric Working Group, said the plans had the potential to make a real difference for children, parents and prescribers.
"Children have the right to the same standards for medicines as adults and this strategy is another step towards achieving this," he added.
(gmcg)
The new paediatric medicines strategy is aimed at encouraging manufacturers of medicines to research and develop medicines geared to the needs of children. They will also make sure prescribers have better information about the impact of medicines on children.
Most medicines are designed for and tested on adults but are widely prescribed for children. The government has said the move is necessary as children and adults "respond very differently to medicines" and that a treatment which is effective in adults may not be as suitable for children.
Under the plans, part of the additional £100 million announced in the Budget to promote research into medicines for children will be invested through new research networks coordinated by the UK Clinical Research Collaboration.
Better information on the use of medicines on children in patient information leaflets and strongly encouraging companies to provide much better paediatric clinical trial data for new and current medicines also form part of the strategy.
Health Minister Lord Warner said: "I want the new strategy that I have announced today to give a strong message to pharmaceutical companies to focus on the needs of children when developing new medicines. Health professionals need the latest information so that they can make the right choices about the medicines and treatments for their younger patients, and that is why the new British National Formulary for Children is so important".
Professor Rosalind Smyth, Chair of the Committee on Safety of Medicines Paediatric Working Group, said the plans had the potential to make a real difference for children, parents and prescribers.
"Children have the right to the same standards for medicines as adults and this strategy is another step towards achieving this," he added.
(gmcg)
Related UK National News Stories
Click here for the latest headlines.
24 May 2006
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency. The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency. The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
23 March 2004
£100m cash boost for NHS mental health research
The NHS will receive an extra £100 million over the next four years for research into Alzheimer's, stroke, diabetes and mental health, the government has announced today. The extra money for research and development was announced in last week's Budget, and will bring combined government spending on medical research to £1.2 billion.
£100m cash boost for NHS mental health research
The NHS will receive an extra £100 million over the next four years for research into Alzheimer's, stroke, diabetes and mental health, the government has announced today. The extra money for research and development was announced in last week's Budget, and will bring combined government spending on medical research to £1.2 billion.
27 March 2008
Infant Cough Medicines Pulled From Shelves
A number of cough and cold remedies aimed at very young children are being removed from shop shelves due to concerns over accidental overdoses.
Infant Cough Medicines Pulled From Shelves
A number of cough and cold remedies aimed at very young children are being removed from shop shelves due to concerns over accidental overdoses.
03 February 2005
Warning issued over hyperactivity treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a warning, after a drug prescribed for children was linked to possible liver damage. Strattera – also known as atomoxetine –was launched in the UK last summer and has been used to treat attention deficit hperactivity disorder (ADHD) in children.
Warning issued over hyperactivity treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a warning, after a drug prescribed for children was linked to possible liver damage. Strattera – also known as atomoxetine –was launched in the UK last summer and has been used to treat attention deficit hperactivity disorder (ADHD) in children.
01 April 2005
Home Office launches crack down on Net paedophiles
The Home Office has announced new measures to protect children from being 'groomed' by internet paedophiles. As part of the plans new Centre for Child Protection on the Internet will be set up to provide support for the police and child protection agencies.
Home Office launches crack down on Net paedophiles
The Home Office has announced new measures to protect children from being 'groomed' by internet paedophiles. As part of the plans new Centre for Child Protection on the Internet will be set up to provide support for the police and child protection agencies.
-
Northern Ireland WeatherThis Evening and Tonight:Showers, scattered in the evening, will clear by midnight leaving the night dry with clear spells. Perhaps a touch of ground frost. Cloud will spread east towards morning. Minimum temperature 2 °C.
